Results 161 to 170 of about 69,829 (275)

Identification of potent multi-target antiviral natural compounds from the fungal metabolites against aspartyl viral polymerases. [PDF]

Sci Rep
Razavi ZS, Ramazani A, Zarei A.
europepmc   +1 more source

Ribavirin plus interferon daily or thrice weekly in chronic hepatitis C genotype 4 [PDF]

, 2000
Ayman Y. Abdel Rahim, Mohsen Salama, Salah El-Dirini, Baher Badawy   +3 more
openalex   +1 more source

High-Pressure Polymorphism of Ribavirin. [PDF]

Cryst Growth Des
Tiwari B, Liermann HP, Parsons S, Giordano N.   +3 more
europepmc   +1 more source

Ribavirin

, 2016
openaire   +1 more source

Interferon Lambda: The Next Frontier in Antiviral Therapy? [PDF]

Pharmaceuticals (Basel)
Chronopoulou S, Tsochantaridis I.
europepmc   +1 more source

Pegylated interferon alfa-2a (PEGASYSTM) and ribavirin combination therapy for chronic hepatitis C: A phase II open-label study

, 2000
Mark Sulkowski, Robert Reindollar, Jie Yu   +2 more
openalex   +1 more source

Evolving landscape of hepatitis C research in the Eastern Mediterranean Region: A comprehensive bibliometric analysis from 2004 to 2024. [PDF]

J Health Popul Nutr
Izadpanah K, Nejadghaderi SA, Sharifi H.
europepmc   +1 more source

SUCCESSFUL RESCUE OF SEVERE RECURRENT HEPATITIS C WITH INTERFERON AND RIBAVIRIN IN A LIVER TRANSPLANT PATIENT

, 2000
Sanshiro Muramatsu, Yonson Ku, Takumi Fukumoto, Takeshi Iwasaki, Masahiro Tominaga, Nobuya Kusunoki, Seitetsu Yoon, Yoshikazu Kuroda   +7 more
openalex   +1 more source

Impact of pH-Responsive Cisplatin/Ribavirin-Loaded Monodispersed Magnetic Silica Nanocomposite on A549 Lung Cancer Cells. [PDF]

Pharmaceutics
Almohazey D, Ravinayagam V, Dafalla H, Balasamy RJ.   +3 more
europepmc   +1 more source

Differential thrombopoietin response to treatment-induced thrombocytopenia: IFN VS. IFN-ribavirin VS. PEG-IFN

, 2000
Anna Kreil, Markus Peck‐Radosavljevic, Harald Hofer, Martina Wichlas, Alfred Gangl, Peter Ferenci   +5 more
openalex   +1 more source